The company will present clinical evidence in young children, pregnancy and type 2 diabetes*
Medtronic plc, the global leader in medical technology, announced it will present new data on its MiniMed™ 780G system at the upcoming European Association for the Study of Diabetes (EASD) 60th Annual Meeting in Madrid on September 9-13. The new clinical evidence on the MiniMed™ 780G system will include areas where the company intends to work with global regulators towards expanding access to its diabetes technology including a lower age for those with type 1 diabetes, and type 2 diabetes.
Today the MiniMed 780G™ system is approved for use in individuals aged 7 years and above with type 1 diabetes. Maintaining stable blood glucose levels is critical for the physical and cognitive development of very young children. By automating insulin delivery, the burden of diabetes on family life, especially during the night, can also be improved.
For women with type 1 diabetes, the challenges to achieving the necessary level of glycemic control in pregnancy to avoid risks to both the mother and the baby extend to delivery and the post-partum period. Pregnant women with type 1 diabetes are advised to aim for tighter control of their glucose levels, typically targeting a range of 63-140 mg/dL (3.5-7.8 mmol/L)1-3, to minimize the risk of high blood sugar levels, which can have adverse effects on the baby's development.
Data will also highlight the ability of the system to reduce burden at mealtimes for people living with diabetes and more real-world evidence demonstrating the ability of the MiniMed 780G™ system to help users achieve their glycemic goals.
SCIENTIFIC DATA
The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research.
MEDTRONIC SPONSORED EVENTS
Medtronic Symposium: “Expanding Horizons in Insulin Therapy: Applications of MiniMed™ 780G system. Monday, September 9, from 13:30-15:00 CET (06:30-08:00 CT) (Venue: Sydney Hall and online), chaired by Prof. Dídac Mauricio, MD PhD, Director of the Department of Endocrinology & Nutrition, Hospital de la Santa Creu i Sant Pau CIBERDEM, Spain and Prof. Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes.
Expert |
Topic |
Prof. Ohad Cohen (Switzerland) |
Meeting the needs of diverse populations |
Prof. Tadej Battelino (Slovenia) |
The MiniMed™ 780G System study in very young children with type 1 diabetes – First results from the LENNY study |
Prof. Tali Cukierman-Yaffe (Israel) |
Using MiniMed™ 780G system in Pregestational Type 1 Diabetes |
Dr. Pablo Mora (US) |
The MiniMed 780G system performance in people living with type 2 diabetes requiring insulin treatment |
* The MiniMed™ 780G system has not been approved for use for children aged 2-6 years, pregnancy, or type 2 diabetes by the FDA or other regulatory bodies.
1 Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019; 42: 1593–603.
2 Benhalima K, Beunen K, Siegelaar SE, et al. Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets. Lancet Diabetes Endocrinol 2023; 11: 490–508.
3 ElSayed NA, Aleppo G, Aroda VR, et al. 15. Management of diabetes in pregnancy: standards of care in diabetes—2023. Diabetes Care 2023; 46 (suppl 1): S254–66.
About the Diabetes Business at Medtronic (www.medtronicdiabetes.com)
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
For more information, contact:
Ashley Patterson
Global Communications
+1-818-576-3025
Ryan Weispfenning
Investor Relations
+1-763-505-4626